<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190268</url>
  </required_header>
  <id_info>
    <org_study_id>P020304</org_study_id>
    <nct_id>NCT00190268</nct_id>
    <nct_alias>NCT00169429</nct_alias>
  </id_info>
  <brief_title>Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis</brief_title>
  <official_title>Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rational of study : 3,4-diaminopyridine is suspected to improved the fatigue associated in
      patient's multiple sclerosis.

      In order to confirm this hypothesis, a randomized, controlled versus placebo, double blinded
      study is performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We proposed a randomized controlled trial between 3,4-diaminopyridine and placebo .

      The main objective : improvement of fatigue by diminution of EMIF-SEP score between the arm
      treatment and placebo arm. The hypothesis tested is that the 3,4-DAP is efficacy in the
      fatigue of multiple sclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of fatigue measured by a decrease of EMIF-SEP score compared to placebo group.</measure>
    <time_frame>43 months</time_frame>
    <description>improvement of fatigue measured by a decrease of EMIF-SEP score compared to placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of safety</measure>
    <time_frame>43 months</time_frame>
    <description>evaluation of safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life impact</measure>
    <time_frame>43 months</time_frame>
    <description>quality of life impact</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>3,4-diaminopyridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,4-diaminopyridine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,4-diaminopyridine</intervention_name>
    <description>3,4-diaminopyridine</description>
    <arm_group_label>3,4-diaminopyridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years and = &lt;60 years

          -  Patients with multiple sclerosis clinically defined and with MIFS-SEP score &gt; 44,
             without deficit sleep and without depression.

          -  Patients without treatment by 3,4-DAP since 3 months

          -  EDSS score &lt; 6

        Exclusion Criteria:

          -  ASAT/ALAT &gt; 2 x ULN

          -  MADRS &gt;= 20

          -  Abnormality cardiac rhythm

          -  Pregnancy

          -  Asthma

          -  Evolutive affection

          -  Renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Cesaro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Henri Mondor-France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Isabelle BRINDEL</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>fatigue</keyword>
  <keyword>3,4-diaminopyridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,4-diaminopyridine</mesh_term>
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

